Director, Cell Therapy Medical, Multiple Myeloma and Solid Tumor Pipeline
Bristol Myers Squibb
2 months ago
Remote friendly (Princeton, NJ)
United States
Medical Affairs
Responsibilities
- Provide WW Medical Affairs therapeutic area expertise and scientific leadership for CAR T compounds in clinical development.
- Lead cross-functional strategy for Multiple Myeloma and/or Solid Tumor pipeline assets; align with local medical affairs teams.
- Develop medical strategy for cell therapy entry into Solid Tumor and provide input to early asset portfolio.
- Drive cross-asset collaboration/knowledge sharing across Cell Therapy and Oncology; build thought-leader relationships.
- Execute medical affairs deliverables: medical plan, publication planning/review, congress strategies, BMS symposia (e.g., COMy/EHA/IMS), refine Integrated Evidence Plan (IEP), update launch materials.
- Lead/support global advisory boards and committee meetings; provide evidence-generation perspective (ISR/CRC trials, HEOR).
- Provide cross-matrix scientific/medical expertise for early and late development; advise on asset/portfolio decisions (MM) and early solid tumor assets (starting with RCC); support market access/marketing content and patient advocacy engagement.
Qualifications & Skills
- MD/PhD/PharmD with clinical and/or 6–8 years Pharma industry experience; Medical Affairs or related experience required.
- CAR-T and Multiple Myeloma knowledge preferred.
- Familiarity with clinical/translational research.
- Strong communication, prioritization, strategic thinking, leadership, and cross-functional collaboration.
- Estimated 15–20% US and global travel.
Benefits (explicit)
- Health coverage (medical/pharmacy/dental/vision), wellbeing support, and 401(k) plus life/disability/insurance; Paid Time Off.
Compensation
- Princeton, NJ (US): $207,490–$251,433.
- Provide WW Medical Affairs therapeutic area expertise and scientific leadership for CAR T compounds in clinical development.
- Lead cross-functional strategy for Multiple Myeloma and/or Solid Tumor pipeline assets; align with local medical affairs teams.
- Develop medical strategy for cell therapy entry into Solid Tumor and provide input to early asset portfolio.
- Drive cross-asset collaboration/knowledge sharing across Cell Therapy and Oncology; build thought-leader relationships.
- Execute medical affairs deliverables: medical plan, publication planning/review, congress strategies, BMS symposia (e.g., COMy/EHA/IMS), refine Integrated Evidence Plan (IEP), update launch materials.
- Lead/support global advisory boards and committee meetings; provide evidence-generation perspective (ISR/CRC trials, HEOR).
- Provide cross-matrix scientific/medical expertise for early and late development; advise on asset/portfolio decisions (MM) and early solid tumor assets (starting with RCC); support market access/marketing content and patient advocacy engagement.
Qualifications & Skills
- MD/PhD/PharmD with clinical and/or 6–8 years Pharma industry experience; Medical Affairs or related experience required.
- CAR-T and Multiple Myeloma knowledge preferred.
- Familiarity with clinical/translational research.
- Strong communication, prioritization, strategic thinking, leadership, and cross-functional collaboration.
- Estimated 15–20% US and global travel.
Benefits (explicit)
- Health coverage (medical/pharmacy/dental/vision), wellbeing support, and 401(k) plus life/disability/insurance; Paid Time Off.
Compensation
- Princeton, NJ (US): $207,490–$251,433.